Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2359 | Local Bone Autograft Wiki | 1.00 |
| drug4703 | ViviGen® Cellular Bone Matrix Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011843 | Radiculopathy NIH | 1.00 |
| D013168 | Spondylolisthesis NIH | 1.00 |
| D013130 | Spinal Stenosis NIH | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0008419 | Intervertebral disc degeneration HPO | 0.71 |
Navigate: Correlations HPO
There is one clinical trial.
The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft in conjunction with an approved Depuy Synthes pedicle screw system compared to autograft mixed with cortical/cancellous allograft in conjunction with the same DePuy Synthes pedicle screw system used for a one or two - level posterolateral lumbar fusion.
Description: Count of participants with successful lumbar bone fusion as measured by CT scan and flexion/extension x-rays at 12-months as evidenced by the following three criteria: bony bridging, no presence of radiolucency and no development of pseudoarthrosis at the treated lumbar level
Measure: Incidence of successful Lumbar Fusion measured radiographically Time: 12 months postoperativeDescription: Equal to or greater than a 2-point decrease in patient reported outcomes as measured by Visual Analog Scale for pain (0-10 point scale, 0 = no pain and 10 = severe amount of pain) from baseline to 12-months.
Measure: Visual Analog Scale for Pain Time: 12 months postoperativeDescription: Equal to or greater than 15-point decrease in patient reported outcomes as measured by Oswestry Disability Index (0-100 point scale, 0 = least amount of disability, 100 = most severe disability) from baseline to 12-months.
Measure: Change in Oswestry Disability Index for Pain and Function Time: 12 months postoperativeDescription: Equal to or greater than 15-point increase in patient reported outcomes as measured by SF-36 (0-100 point scale, 0 = low favorable health state and 100 = most favorable health state) from baseline to 12-months.
Measure: Change in Short Form Health Survey-36 for Quality of Life Time: 12 months postoperativeDescription: Count of participants with new or worsening neurological (lumbar motor and sensory) deficit as evaluated by lumbar spine neurological exam from baseline through 12 months.
Measure: Neurological Deficit per Lumbar Spine Neurological Exam Time: 12 months postoperativeDescription: Count of participants with revision surgery by month 12
Measure: Count of participants with revision surgery by month 12 Time: 12 months postoperativeDescription: Count of participants developing pseudoarthrosis by month 12
Measure: Count of participants developing pseudoarthrosis by month 12 Time: 12 months postoperativeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports